R1 Therapeutics Taps Elite Experts to Fast-Track Novel Kidney Disease Drug

REDWOOD CITY, Calif. – June 30, 2026 – In a move signaling significant confidence and strategic acceleration, clinical-stage biopharmaceutical company R1 Therapeutics has assembled a "dream team" of nephrology experts to guide its lead drug candidate, AP306, through a pivotal stage of development. The company announced the formation of a world-class Scientific Advisory Board (SAB) just as it prepares to launch a global Phase 2b clinical trial for the first-in-class therapy, which targets a dangerous and poorly managed complication of chronic kidney disease (CKD).

This strategic assembly of scientific minds, backed by a hefty $77.5 million Series A financing round that closed in March, positions the young company to make a serious run at solving a persistent problem for millions of dialysis patients worldwide. The formation of the board is a powerful vote of confidence from the highest echelons of kidney disease research, providing crucial validation for R1's innovative approach.

A Board Built for a Breakthrough

R1 Therapeutics has not just formed an advisory board; it has curated a powerhouse of seven internationally renowned leaders in nephrology. The board is chaired by Dr. Glenn M. Chertow, a luminary from Stanford University School of Medicine, whose work has shaped clinical practice and research in kidney disease for decades.

"Bringing together this caliber of scientific leadership is a major milestone for R1," said Krishna Polu, M.D., Co-Founder, President and CEO of R1 Therapeutics. "Their collective experience in advancing novel therapies through clinical development and their specific expertise in the field of CKD-Mineral Bone Disorder and Dialysis will be instrumental as we progress AP306 into global Phase 2b trials and beyond."

The board's composition reads like a who's who of global nephrology. Members include Dr. Sharon M. Moe of Indiana University School of Medicine, a key figure in defining CKD-Mineral and Bone Disorder (CKD-MBD); Dr. Markus Ketteler from Germany, a leading researcher on cardiovascular disease in CKD; and Dr. Li Zuo of Peking University People's Hospital, who heads major nephrology and blood purification initiatives in China. This international roster underscores the global nature of the problem R1 aims to solve and its ambition for a worldwide impact.

For a relatively new company, attracting such talent is a strategic coup. It provides a layer of scientific validation that goes beyond press releases, signaling to investors, partners, and the broader medical community that the science behind AP306 is sound and its potential is significant. This expert guidance will be critical as the company navigates the complexities of a large-scale, international clinical trial.

A Novel Weapon Against a Silent Killer

The target of AP306 is hyperphosphatemia, a condition where patients with end-stage kidney disease are unable to excrete phosphate, causing it to build up to dangerous levels in the blood. This complication is far from benign; uncontrolled phosphate is a primary driver of cardiovascular disease—the leading cause of death in dialysis patients—and severe bone disorders. Research indicates that the condition is associated with a 4- to 14-fold increased risk of bone fractures and a staggering 10- to 30-times higher risk of cardiovascular mortality.

For decades, the standard of care has been a combination of dietary restrictions and "phosphate binders"—medications that patients must take with every meal to bind to phosphate in the gut and prevent its absorption. However, these binders come with a heavy price: a massive pill burden, significant gastrointestinal side effects, and often, inadequate control. Many patients struggle to adhere to the regimen and fail to reach their target phosphate levels, leaving them vulnerable to the condition's devastating consequences.

AP306 represents a fundamentally different strategy. As a first-in-class pan phosphate transporter inhibitor, it doesn't just bind to phosphate after the fact. Instead, it is designed to proactively block its absorption by targeting three key phosphate transporters in the gut.

"Hyperphosphatemia remains a persistent and under-addressed challenge in the management of chronic kidney disease, with many patients unable to achieve adequate control with current therapies," noted Dr. Chertow, the newly appointed SAB Chair. "AP306 represents a genuinely novel approach by blocking the active transport of phosphate. I look forward to working with R1 and my fellow Board members to help translate this potential into meaningful benefits for patients." Early Phase 2a data has already shown that AP306 can produce significant reductions in serum phosphate with a good safety profile, bolstering hopes for this new mechanism.

The Business of Innovation: Smart Money and Strategic Alliances

R1 Therapeutics launched in March 2026 not with a whisper, but with a bang: an oversubscribed $77.5 million Series A financing. The list of investors is as impressive as its new advisory board. The round was co-led by top-tier life sciences investors Abingworth, DaVita Venture Group, and F-Prime.

The inclusion of DaVita Venture Group and U.S. Renal Care—two of the largest kidney care providers in the world—is particularly telling. It’s a clear signal of "smart money" at work, with the very organizations that treat these patients daily investing in a potential solution. This not only provides capital but also offers an invaluable strategic advantage, creating a potential pathway for clinical trial recruitment and future market adoption.

The company's asset itself, AP306, was acquired through a savvy licensing deal. R1 secured exclusive global rights (outside of Greater China) from Alebund Pharmaceuticals, which retains rights in that region. This allows R1 to focus its considerable resources on development in major global markets while collaborating with a partner focused on a key territory. The company is led by CEO Krishna Polu, a nephrologist with deep industry experience, ensuring that both clinical insight and business acumen are at the helm.

The Road Ahead: Navigating a Pivotal Trial

With its expert board in place and coffers full, R1 is now focused on the next critical hurdle: a global Phase 2b clinical trial. This stage of drug development is where many promising therapies falter. The trial, registered as NCT06712654, is designed as a randomized, double-blind, placebo-controlled study to rigorously evaluate the efficacy, safety, and optimal dosing of AP306 in dialysis patients with hyperphosphatemia.

Successfully navigating this phase will provide the robust data needed to proceed to larger, more expensive Phase 3 trials—the final step before seeking regulatory approval. The global scope of the trial indicates R1's intent to file for approval with regulatory bodies like the U.S. FDA and the European Medicines Agency simultaneously, accelerating its path to patients.

For the more than four million people worldwide on dialysis, the current options for managing hyperphosphatemia are burdensome and often insufficient. R1 Therapeutics, by combining a novel scientific approach with strong financial backing and elite-level expertise, is making a calculated and compelling push to change that reality. The initiation of its Phase 2b trial will be a closely watched milestone in the quest for a better standard of care for patients with chronic kidney disease.